Latest Shareholder Confidence News

WasteCo Group is raising $2 million through a share placement at $0.007 per share to finance a comprehensive turnaround and expansion plan amid ongoing financial challenges and a leadership overhaul.

WasteCo Group has initiated a $2 million share placement at $0.007 per share to fund its ambitious turnaround and growth strategy amid a FY 2026 loss. A Share Purchase Plan will follow, offering existing investors a chance to participate on the same terms.

Alliance Aviation Services has launched the retail tranche of its fully underwritten $40 million equity raising, offering shareholders new shares at $0.70 each to reinforce its balance sheet and support ongoing turnaround efforts.

Cygnus Metals receives conditional TSX listing approval for Central Asia Metals shares amid unchanged positive expert opinion on the acquisition scheme.

ASX Limited has updated its FY26 final dividend reinvestment plan (DRP) participation rate to 32.93%, increasing the total DRP size to $106.1 million, supported by continued underwriting from Barrenjoey Markets.

Starpharma has successfully completed a $32 million entitlement offer, nearly fully subscribed, to fund its DEP® HER2-Lutetium Phase 1 trial and further develop its oncology pipeline.

Spenda Limited has reshaped its business with significant cost cuts, divested non-core assets, and secured major shareholder backing, positioning itself for cash flow positive operations.

The Takeovers Panel has received an application alleging undisclosed associations and possible breaches of takeover laws following a massive off-market transfer of Adslot shares valued at $723,870.

ClearVue Technologies has exceeded its $1 million target in a Share Purchase Plan, raising $1.29 million and issuing over 14.6 million shares with free attaching options pending shareholder approval.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

SDI Limited shareholders voted overwhelmingly in favour of a $1.40 per share acquisition scheme by InnoXvest Dental, setting the stage for court approval and delisting.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.